Life Sciences Tools and Services
Company Overview of WaferGen Bio-systems, Inc.
WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for single-cell analysis and clinical research in the United States, Canada, Europe, and the Asia Pacific. It offers SmartChip Real-Time polymerase chain reaction (PCR) system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of PCR. The company’s SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data fr...
7400 Paseo Padre Parkway
Fremont, CA 94555
Founded in 2002
Key Executives for WaferGen Bio-systems, Inc.
Secretary, Treasurer and Director
Compensation as of Fiscal Year 2016.
WaferGen Bio-systems, Inc. Key Developments
Wafergen Bio-Systems Files Form 15
Mar 13 17
Wafergen Bio-Systems, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.001 par value under the Securities Exchange Act of 1934, as amended.
WaferGen Bio-Systems, Inc. Announces Executive Changes
Mar 1 17
WaferGen Bio-systems, Inc. announced that in connection with the consummation of the Merger and in accordance with the Merger Agreement, each of the then-current directors of the Company resigned from their positions as directors of the Company effective as of the Effective Time. These resignations were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices. Pursuant to the Merger Agreement, at the Effective Time, Carol Lou, Frank Raab, Kazuki Yamamoto, Shuichiro Matsuzaki and Junichi Mineno became the directors of the Company. In addition, effective as of the Effective Time, all of the executive officers of the Company were removed from their respective positions as executive officers, and Carol Lou became the President of the Company and Frank Raab became the Secretary and Treasurer of the Company.
WaferGen Bio-systems Intends To File With SEC A Certification On Form 15
Mar 1 17
On February 28, 2017, WaferGen Bio-systems, Inc. (Company) notified the NASDAQ Stock Market LLC (NASDAQ) of the consummation of the Merger and requested that NASDAQ halt trading of the Common Stock effective prior to market open on March 1, 2017 and suspend trading of the Common Stock effective prior to market open on March 2, 2017 and file with the SEC a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act). The Company intends to file with the SEC a certification on Form 15 under the Exchange Act, requesting the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the Common Stock.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 13, 2016